Leyden Laboratories BV

Leyden Laboratories B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of nasal sprays designed to provide broad protection against respiratory viruses. Utilizing its Mucosal Protection Platform, Leyden Labs aims to deliver antibody-based nasal sprays that offer immediate protection by targeting the respiratory mucosa, effectively blocking viruses at their point of entry. This innovative approach is particularly beneficial for vulnerable populations, such as the elderly and immunocompromised, and remains effective even as viruses mutate. The company's lead product candidate, CR9114, is a human monoclonal antibody licensed from Janssen Pharmaceuticals, demonstrating promising protection against influenza in preclinical models.